At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 39 enrolled
Drug / intervention
Interferon beta-1b (Betaseron, BAY86-5046)drug
Likely dose
Interferon beta-1b (Betaseron, BAY86-5046) 250 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Study to Evaluate the Effect, Safety and Tolerability of 250µg (8 MIU) Interferon Beta 1b (Betaferon) Given Subcutaneously Every Other Day (for 24 Weeks) in Patients of Chinese Origin With Multiple Sclerosis
In Brief
A Phase 3 clinical trial evaluating Interferon beta-1b (Betaseron, BAY86-5046) for Multiple Sclerosis. Completed, enrolled 39 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine if the study drug is effective and safe in the treatment of Multiple Sclerosis (MS) in patients of Chinese origin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2006
Enrollment StartNov 2006
Primary CompletionSep 2008
TodayJul 2026
First PostedAug 30, 2006
Enrollment StartNov 1, 2006
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.8 years ago
Interventions
Interferon beta-1b (Betaseron, BAY86-5046)drug
Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)